Page last updated: 2024-10-17

coumarin and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

coumarin has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies

2H-chromen-2-one: coumarin derivative

Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
HYNIE, J1
CERMAK, L1
GREGOR, O1
POKORNY, J1

Other Studies

1 other study available for coumarin and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

ArticleYear
[Anticoagulant therapy of priapism with pelentan in chronic myeloid leukemia].
    Casopis lekaru ceskych, 1952, Oct-31, Volume: 91, Issue:44

    Topics: Anticoagulants; Coumarins; Ethyl Biscoumacetate; Humans; Leukemia; Leukemia, Myelogenous, Chronic, B

1952